Skip to main content
. 2023 Nov 16;52(D1):D1503–D1507. doi: 10.1093/nar/gkad1017

Figure 1.

Figure 1.

Example outputs for Thalidomide (Withdrawn ID w136). (A) Adverse effects extracted from the FAERS database; (B) extracted and filtered human ChEBML targets of Thalidomide (B) and its S-enantiomer (C) and reported human disease pathways (D) of Thalidomide S-enantiomer, obtained by enriched pathway analysis using KEGG pathways and druggable targets.